Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7

ConclusionBaricitinib improved patient-reported skin pain severity as early as day 2.ClinicalTrials.gov identifiersBREEZE-AD1, NCT03334396; BREEZE-AD2, NCT03334422; BREEZE-AD7, NCT03733301.

http://rd.springer.com/10.1007/s13555-021-00577-x

Source: Dermatology and Therapy - October 1, 2021 Category: Dermatology Source Type: research